EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition

Yu-Li Lo, Ci-Jheng Hong, Chen-Shen Wang, Ching-Ping Yang

Archives of Pharmacal Research · 2024-11 · 47 (10-11) · 829-853

DOI: 10.1007/s12272-024-01514-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Pharmacal Research, online erschienen am 01.11.2024. Verfasst von Yu-Li Lo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan. yulilo@nycu.edu.tw. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Docetaxel, ErbB Receptors, Polyethylene Glycols. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, National Yang Ming Chiao Tung University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human antigen R (HuR), an RNA-binding protein, is implicated in regulating mRNA stability and translation in cancer, especially in triple-negative breast cancer (TNBC), a highly aggressive form. CRISPR/Cas9-mediated HuR knockout (HuR CRISPR) presents a promising genetic therapeutic approach, but it encounters transfection limitations. Docetaxel (DTX), an effective cytotoxic agent against metastatic breast cancer (BC), faces challenges related to vehicle-associated adverse events in DTX formulations. Therefore, we designed multifunctional nanoparticles with pH-sensitive PEG derivatives and targeting peptides to enable efficient HuR CRISPR and DTX delivery to human TNBC MDA-MB-231 cells and tumor-bearing mice. Our findings indicated that these nanoparticles displayed pH-responsive cytotoxicity, precise EGFR targeting, efficient tumor penetration, successful endosomal escape, and accurate nuclear and cytoplasmic localization. They also demonstrated the ability to spare normal cells and prevent hemolysis. Our study concurrently modulated multiple pathways, including EGFR, Wnt/β-catenin, MDR, and EMT, through the regulation of EGFR/PI3K/AKT, HuR/galectin-3/GSK-3β/β-catenin, and P-gp/MRPs/BCRP, as well as YAP1/TGF-β/ZEB1/Slug/MMPs. The combined treatment arrested the cell cycle at the G2 phase and inhibited EMT, effectively impeding tumor progression. Tissue distribution, biochemical assays, and histological staining revealed the enhanced safety profile of pH-responsive PEG- and peptide-modified nanoformulations in TNBC mice. The DTX-embedded and peptide-modified nanoparticles mitigated the side effects of DTX, enhanced cytotoxicity in TNBC MDA-MB-231 cells, and exhibited remarkable antitumor efficacy and safety in TNBC-bearing mice with HuR CRISPR deletion. Collectively, the combination therapy of DTX and CRISPR/Cas9 offers an effective platform for delivering antineoplastic agents and gene-editing systems to combat tumor resistance and progression in TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsDocetaxelErbB ReceptorsPolyethylene GlycolsAntineoplastic AgentsCRISPR-Cas SystemsNanoparticlesAnimalsHumansMiceFemaleCell Line, TumorMice, NudeMice, Inbred BALB CELAV-Like Protein 1Drug Delivery SystemsCell Proliferation

Stichwörter der Autor:innen

ChemotherapyEpidermal growth factor receptor (EGFR)HuR knockout by CRISPR/Cas9ProgressionTriple-negative breast cancerpH-sensitive targeting nanoparticle

Substanzen

DocetaxelErbB ReceptorsPolyethylene GlycolsAntineoplastic AgentsEGFR protein, humanELAV-Like Protein 1

Autor:innen und Institutionen

  • Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan. yulilo@nycu.edu.tw.
  • Faculty of Pharmacy, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan. yulilo@nycu.edu.tw.
  • Institute of Pharmacology, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.
  • Department of Pharmacy, Antai Medical Care Corporation Antai Tian-Sheng Memorial Hospital, Pingtung, Taiwan.

Förderung

  • National Science and Technology Council
  • National Yang Ming Chiao Tung University

Zitieren

APA

Lo, Y. L., Hong, C. J., Wang, C. S., & Yang, C. P. (2024). Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition. Archives of Pharmacal Research, 47(10-11), 829-853. https://doi.org/10.1007/s12272-024-01514-0

Vancouver

Lo YL, Hong CJ, Wang CS, Yang CP. Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition. Archives of Pharmacal Research. 2024;47(10-11):829-853. doi:10.1007/s12272-024-01514-0

BibTeX
@article{Lo2024,
  author = {Lo, Yu-Li and Hong, Ci-Jheng and Wang, Chen-Shen and Yang, Ching-Ping},
  title = {Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition},
  journal = {Archives of Pharmacal Research},
  year = {2024},
  volume = {47},
  number = {10-11},
  pages = {829--853},
  doi = {10.1007/s12272-024-01514-0}
}
Kostenlos starten →